Immune Responses to Vaccine-preventable Diseases Among Toddlers and Preschool Children After Primary Immunization and First Booster in Northwestern Algiers, Algeria

Overview

Journal Heliyon

Specialty Social Sciences

Date 2018 Jul 13

PMID 29998194

Citations 1

Authors

Nabila Benamrouche

Hassiba Tali Maamar

Samia Chemli

Houria Senouci

Kheira Rahal

Affiliations

Soon will be listed here.

Abstract

Objectives: To determine immune responses to selected vaccine-preventable communicable diseases: pertussis, diphtheria and type b (Hib) in Algerian toddlers and preschool children after primary vaccination and first booster, recruited from three local healthcare facilities in Northwestern Algiers.

Methods: The information of demographic characteristics and vaccination status were collected for each subject by questionnaire. Specific antibody levels and Hib antibody avidity were determined using commercial ELISA kits.

Results: A total of eighty-one subjects aged between 19 and 55 months were studied. Almost all subjects were fully protected against diphtheria (76/81; 93.83%; 95% CI: 86.35-97.33) and invasive Hib disease (29/30; 96.67%; 95% CI: 83.33-99.41), while only 20/78 (25.64%; 95% CI: 17.26-36.31) had anti-PT (pertussis toxin) antibody levels above 25 IU/ml. A significant decrease of anti-PT antibody levels was observed until the age of 36 months ( = 0.02). GMTs (geometric mean titers) of anti-PT antibodies were low, but remain significantly higher in children ≤36 months of age ( = 0.02). Both GMT and rates of ≥0.15 μg/ml, ≥1 μg/ml, and ≥5 μg/ml titers were significantly higher in Hib-vaccinated subjects ( < 0.01). Relative Hib-avidity index (≥50%) and GMAI (geometric mean avidity index) were high in both Hib-vaccinated and -unvaccinated groups.

Conclusions: As shown in the present study, young children were fully protected against diphtheria and Hib, but showed low immunity to pertussis. Further sero-epidemiological studies including a large number of subjects with a wider range of age are needed to explore the immunity level in older children, adolescents and adults.

Citing Articles

Evaluation of the Potency of the Pertussis Vaccine in Experimental Infection Model with : Study of the Case of the Pertussis Vaccine Used in the Expanded Vaccination Program in Algeria.

Tahar Djebbar K, Allouache M, Kezzal S, Benguerguoura F, TouilBoukoffa C, Zidi I Vaccines (Basel). 2022; 10(6).

PMID: 35746514 PMC: 9230502. DOI: 10.3390/vaccines10060906.

References

Gajdos V, Vidor E, Richard P, Tran C, Sadorge C . Diphtheria, tetanus and poliovirus antibody persistence 5 years after vaccination of pre-schoolers with two different diphtheria, tetanus and inactivated poliomyelitis vaccines (Td-IPV or DT-IPV) and immune responses to a booster dose of DTaP-IPV. Vaccine. 2015; 33(32):3988-96. DOI: 10.1016/j.vaccine.2015.06.036. View

Benamrouche N, Tali Maamar H, Lazri M, Hasnaoui S, Radoui A, Lafer O . Pertussis in north-central and northwestern regions of Algeria. J Infect Dev Ctries. 2016; 10(11):1191-1199. DOI: 10.3855/jidc.7262. View

Sharma H, Yadav S, Lalwani S, Kapre S, Jadhav S, Parekh S . Antibody persistence of two pentavalent DTwP-HB-Hib vaccines to the age of 15-18 months, and response to the booster dose of quadrivalent DTwP-Hib vaccine. Vaccine. 2012; 31(3):444-7. DOI: 10.1016/j.vaccine.2012.11.038. View

Guiso N . Bordetella pertussis: why is it still circulating?. J Infect. 2013; 68 Suppl 1:S119-24. DOI: 10.1016/j.jinf.2013.09.022. View

Simondon F, Preziosi M, Yam A, Kane C, Chabirand L, Iteman I . A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine. 1997; 15(15):1606-12. DOI: 10.1016/s0264-410x(97)00100-x. View

Sow S, Tapia M, Diallo S, Keita M, Sylla M, Onwuchekwa U . Haemophilus influenzae Type B conjugate vaccine introduction in Mali: impact on disease burden and serologic correlate of protection. Am J Trop Med Hyg. 2009; 80(6):1033-8. View

Senouci H, Lounici M, Rahal K . [Antidiphtheria immunity of the Algerian population: a seroepidemiological study]. Med Mal Infect. 2005; 34(7):316-20. View

van den Hof S, de Melker H, Berbers G, van der Kraak P, Spaendonck M . Antibodies to Haemophilus influenzae serotype b in the Netherlands a few years after the introduction of routine vaccination. Clin Infect Dis. 2000; 32(1):2-8. DOI: 10.1086/317538. View

Edwards K, Meade B, Decker M, Reed G, Rennels M, Steinhoff M . Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics. 1995; 96(3 Pt 2):548-57. View

10.

Gaayeb L, Sarr J, Ndiath M, Hanon J, Debrie A, Seck M . Seroprevalence of pertussis in Senegal: a prospective study. PLoS One. 2012; 7(10):e48684. PMC: 3485356. DOI: 10.1371/journal.pone.0048684. View

11.

Grimprel E, Begue P, Anjak I, Njamkepo E, Francois P, Guiso N . Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clin Diagn Lab Immunol. 1996; 3(1):93-7. PMC: 170254. DOI: 10.1128/cdli.3.1.93-97.1996. View

12.

Almeida A, Trindade E, B Vitor A, Tavares M . Haemophilus influenzae type b meningitis in a vaccinated and immunocompetent child. J Infect Public Health. 2016; 10(3):339-342. DOI: 10.1016/j.jiph.2016.06.001. View

13.

Guiso N, De La Rocque F, Njamkepo E, Lecuyer A, Levy C, Romain O . Pertussis surveillance in private pediatric practices, France, 2002-2006. Emerg Infect Dis. 2008; 14(7):1159-61. PMC: 2600362. DOI: 10.3201/eid1407.071246. View

14.

Guiso N, Njamkepo E, Vie le Sage F, Zepp F, Meyer C, Abitbol V . Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine. 2006; 25(8):1390-7. DOI: 10.1016/j.vaccine.2006.10.048. View

15.

Guiso N, Levy C, Romain O, Guillot S, Werner A, Rondeau M . Whooping cough surveillance in France in pediatric private practice in 2006-2015. Vaccine. 2017; 35(45):6083-6088. DOI: 10.1016/j.vaccine.2017.09.072. View

16.

Lee Y, Kelly D, Yu L, Slack M, Booy R, Heath P . Haemophilus influenzae type b vaccine failure in children is associated with inadequate production of high-quality antibody. Clin Infect Dis. 2008; 46(2):186-92. DOI: 10.1086/524668. View

17.

Purohit P, Al-Obaid I, Omar N . The first reported case of possible Haemophilus influenzae type b vaccine failure from Kuwait and literature-review. J Infect Public Health. 2013; 7(2):99-105. DOI: 10.1016/j.jiph.2013.07.009. View

18.

Baggett H, Hennessy T, Bulkow L, Romero-Steiner S, Hurlburt D, Holder P . Immunologic response to Haemophilus influenzae type b (Hib) conjugate vaccine and risk factors for carriage among Hib carriers and noncarriers in Southwestern Alaska. Clin Vaccine Immunol. 2006; 13(6):620-6. PMC: 1489551. DOI: 10.1128/CVI.00077-06. View

19.

Ladhani S, Ramsay M, Flood J, Campbell H, Slack M, Pebody R . Haemophilus influenzae serotype B (Hib) seroprevalence in England and Wales in 2009. Euro Surveill. 2012; 17(46). DOI: 10.2807/ese.17.46.20313-en. View

20.

Hammitt L, Crane R, Karani A, Mutuku A, Morpeth S, Burbidge P . Effect of Haemophilus influenzae type b vaccination without a booster dose on invasive H influenzae type b disease, nasopharyngeal carriage, and population immunity in Kilifi, Kenya: a 15-year regional surveillance study. Lancet Glob Health. 2016; 4(3):e185-94. PMC: 4763163. DOI: 10.1016/S2214-109X(15)00316-2. View